William H. Lagarde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William H. Lagarde has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Billie M. Moats‐Staats
Department of Pediatrics The University of North Carolina at Chapel Hill Chapel Hill NC 27599‐7039 United States
2 shared publicationsA. Joseph D'ERcole
Department of Pediatrics The University of North Carolina at Chapel Hill Chapel Hill NC 27599‐7039 United States
1 shared publicationAli S. Calikoglu
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
1 shared publicationAnn T. Heerens
Department of Pediatrics The University of North Carolina at Chapel Hill Chapel Hill NC 27599‐7039 United States
1 shared publicationLouis E. Underwood
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
1 shared publicationPing Ye
Department of Pediatrics The University of North Carolina at Chapel Hill Chapel Hill NC 27599‐7039 United States
1 shared publication
Latest Publications
- 7 January 2007
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 25 (2) , 95-105
A non‐transformed oligodendrocyte precursor cell line, OL‐1, facilitates studies of insulin‐like growth factor‐I signaling during oligodendrocyte development
The process by which oligodendrocyte progenitors differentiate into mature oligodendrocytes is complex and incompletely understood in part because of the paucity of oligodendrocyte precursors cell lines that can be studied in culture. We have developed a non‐immortalized rat oligodendrocyte precursor line, called OL‐1, which behaves in a fashion consistent with developing oligodendrocytes in vivo. This OL‐1 line provides a model for the study of oligodendrocyte development and offers an alternative to the CG‐4 cell line. When OL‐1 cells are propagated in conditioned growth media, they have morphology consistent with immature oligodendrocytes and exhibit A2B5 antigen positive and myelin basic protein‐negative immunoreactivity. Withdrawal of conditioned growth media and culture in serum‐free medium results in OL‐1 cell maturation, manifested by a shift to myelin basic protein‐positive immunoreactivity, A2B5 antigen‐negative immunoreactivity, decreased NG2 mRNA expression, increased expression of proteolipid protein mRNA, and increased expression of CNP protein. In addition, the expression of proteolipid protein and its splicing variant DM‐20 exhibit a pattern that is similar to brain proteolipid protein expression during development. When OL‐1 cells are exposed to Insulin‐like growth factor‐I, there are significant increases in proteolipid protein mRNA expression (p < 0.05), the number of cell processes (p < 0.05), and cell number (p < 0.05). Treatment with the caspase inhibitors Z‐DEVD‐FMK and Z‐VAD‐FMK (inhibitors of caspases 3, 6, 7, 8, 10 and 1, 3, 4, respectively), Insulin‐like growth factor‐I, or both, results in a similar increase in cell number. Because Insulin‐like growth factor‐I does not substantially increase the BrdU labeling of OL‐1 cells, these data collectively indicate that Insulin‐like growth factor‐I increases OL‐1 cell number predominately by promoting survival, rather than stimulating proliferation. This non‐immortalized oligodendrocyte precursor cell line, therefore, exhibits behavior consistent with the in vivo development of oligodendrocytes and provides an excellent model for the study of developing oligodendrocytes.
- 7 January 2007
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 25 (2) , 95-105
A non‐transformed oligodendrocyte precursor cell line, OL‐1, facilitates studies of insulin‐like growth factor‐I signaling during oligodendrocyte development
The process by which oligodendrocyte progenitors differentiate into mature oligodendrocytes is complex and incompletely understood in part because of the paucity of oligodendrocyte precursors cell lines that can be studied in culture. We have developed a non‐immortalized rat oligodendrocyte precursor line, called OL‐1, which behaves in a fashion consistent with developing oligodendrocytes in vivo. This OL‐1 line provides a model for the study of oligodendrocyte development and offers an alternative to the CG‐4 cell line. When OL‐1 cells are propagated in conditioned growth media, they have morphology consistent with immature oligodendrocytes and exhibit A2B5 antigen positive and myelin basic protein‐negative immunoreactivity. Withdrawal of conditioned growth media and culture in serum‐free medium results in OL‐1 cell maturation, manifested by a shift to myelin basic protein‐positive immunoreactivity, A2B5 antigen‐negative immunoreactivity, decreased NG2 mRNA expression, increased expression of proteolipid protein mRNA, and increased expression of CNP protein. In addition, the expression of proteolipid protein and its splicing variant DM‐20 exhibit a pattern that is similar to brain proteolipid protein expression during development. When OL‐1 cells are exposed to Insulin‐like growth factor‐I, there are significant increases in proteolipid protein mRNA expression (p < 0.05), the number of cell processes (p < 0.05), and cell number (p < 0.05). Treatment with the caspase inhibitors Z‐DEVD‐FMK and Z‐VAD‐FMK (inhibitors of caspases 3, 6, 7, 8, 10 and 1, 3, 4, respectively), Insulin‐like growth factor‐I, or both, results in a similar increase in cell number. Because Insulin‐like growth factor‐I does not substantially increase the BrdU labeling of OL‐1 cells, these data collectively indicate that Insulin‐like growth factor‐I increases OL‐1 cell number predominately by promoting survival, rather than stimulating proliferation. This non‐immortalized oligodendrocyte precursor cell line, therefore, exhibits behavior consistent with the in vivo development of oligodendrocytes and provides an excellent model for the study of developing oligodendrocytes.
- 29 September 2003
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 125A (3) , 299-305
Novel mutation in the SLC19A2 gene in an African‐American female with thiamine‐responsive megaloblastic anemia syndrome
Thiamine‐responsive megaloblastic anemia (TRMA) syndrome is an autosomal recessive disorder characterized by diabetes mellitus (DM), progressive sensorineural deafness, and thiamine‐responsive anemia. Mutations in the SLC19A2 gene encoding a high‐affinity thiamine transporter protein THTR‐1 are responsible for the clinical features associated with TRMA syndrome. We report an African‐American female with TRMA‐syndrome associated with thyroid disease and retinitis pigmentosa caused by a novel mutation in the SLC19A2 gene. The patient presented at 12 months of age with paroxysmal atrial tachycardia and hepatosplenomegaly. One month later, she developed DM requiring intermittent insulin therapy. At 2‐1/2 years of age, profound sensorineural hearing loss was discovered. By 4 years of age, daily insulin therapy (0.5 U/kg/day) was instituted and her insulin requirement gradually increased to 1.0 U/kg/day by 9 years of age. She developed optic atrophy, retinitis pigmentosa, and visual impairment by 12 years of age with severe restriction of peripheral vision by 16 years. At age 19, a thiamine‐responsive normocytic anemia was discovered. She was diagnosed with autoimmune thyroiditis at 20 years and she experienced a psychotic episode associated with a mood disorder at age 21. With oral thiamine therapy, her insulin requirement decreased by 30% over a 20 month period. Molecular analysis revealed that the patient is homozygous for a missense mutation (C152T) in exon 1 of the SLC19A2 gene.
- 29 September 2003
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 125A (3) , 299-305
Novel mutation in the SLC19A2 gene in an African‐American female with thiamine‐responsive megaloblastic anemia syndrome
Thiamine‐responsive megaloblastic anemia (TRMA) syndrome is an autosomal recessive disorder characterized by diabetes mellitus (DM), progressive sensorineural deafness, and thiamine‐responsive anemia. Mutations in the SLC19A2 gene encoding a high‐affinity thiamine transporter protein THTR‐1 are responsible for the clinical features associated with TRMA syndrome. We report an African‐American female with TRMA‐syndrome associated with thyroid disease and retinitis pigmentosa caused by a novel mutation in the SLC19A2 gene. The patient presented at 12 months of age with paroxysmal atrial tachycardia and hepatosplenomegaly. One month later, she developed DM requiring intermittent insulin therapy. At 2‐1/2 years of age, profound sensorineural hearing loss was discovered. By 4 years of age, daily insulin therapy (0.5 U/kg/day) was instituted and her insulin requirement gradually increased to 1.0 U/kg/day by 9 years of age. She developed optic atrophy, retinitis pigmentosa, and visual impairment by 12 years of age with severe restriction of peripheral vision by 16 years. At age 19, a thiamine‐responsive normocytic anemia was discovered. She was diagnosed with autoimmune thyroiditis at 20 years and she experienced a psychotic episode associated with a mood disorder at age 21. With oral thiamine therapy, her insulin requirement decreased by 30% over a 20 month period. Molecular analysis revealed that the patient is homozygous for a missense mutation (C152T) in exon 1 of the SLC19A2 gene.